`To:
`Cc:
`
`Subject:
`Date:
`
`Trials
`Queler, Maureen; Trials
`Feldstein, Mark; Yang, Yieyie; Goldberg, Joshua; sparmelee@wsgr.com; "mrosato@wsgr.com";
`jmills@wsgr.com; stewart_mark@lilly.com
`RE: Mylan Pharmaceuticals Inc. v. ICOS Corp. - IPR2017-00323
`Monday, February 27, 2017 11:18:57 AM
`
`Counsel,
`
`The dates run from December 12th. I apologize for any confusion.
`
`Regards,
`
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`
`From: Queler, Maureen [mailto:Maureen.Queler@finnegan.com]
`Sent: Friday, February 24, 2017 2:28 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Feldstein, Mark <mark.feldstein@finnegan.com>; Yang, Yieyie <Yieyie.Yang@finnegan.com>;
`Goldberg, Joshua <Joshua.Goldberg@finnegan.com>; Queler, Maureen
`<Maureen.Queler@finnegan.com>; sparmelee@wsgr.com; 'mrosato@wsgr.com'
`<mrosato@wsgr.com>; jmills@wsgr.com; stewart_mark@lilly.com
`Subject: Mylan Pharmaceuticals Inc. v. ICOS Corp. - IPR2017-00323
`
`Sir/Madam,
`
`Counsel for Patent Owner would like clarification on the due date for its preliminary response. The
`Notice of Filing Date Accorded is dated December 9th and states that the due date for the
`preliminary response is three months from the date of the notice. However, the Notice was not
`provided (uploaded to the USPTO’s E2E system) until December 12th. Patent Owner would
`therefore like to confirm that the preliminary response is not due until March 12th, three months
`from the actual date notice was given. Counsel for Patent Owner is available for a call with the
`Board to discuss this issue, if necessary.
`
`Best regards,
`
`Maureen
`
`Maureen D. Queler
`Attorney at Law
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW, Washington, DC 20001-4413
`
`ICOS Exhibit 2011
`Mylan v. ICOS
`IPR2017-00323
`
`Page 1 of 2
`
`
`
`+1 202 408 4294 | fax +1 202 408 4400 | maureen.queler@finnegan.com | www.finnegan.com
`
`
`
`This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged,
`confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have received this message in
`error, please advise the sender by return e-mail and delete it from your mailbox. Thank you.
`
`Page 2 of 2
`
`